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Abstract 
 An increasing body of evidence suggests that astrocytes play a key role in 
modulating neuronal fate during acute and chronic neurodegenerative 
conditions.  Following CNS injury, an upregulation of p53 has been noted in 
both neurons and reactive astrocytes. p53 is an extremely important protein in 
determining cell fate decisions and its activation can result in the 
transcriptional induction of target genes that regulate apoptosis, autophagy, 
premature senescence and cell-cycle arrest. We found that p53 is upregulated 
in primary cortical astrocytes following oxidative stress and DNA damage and 
that this upregulation results in the p53-dependent transcriptional induction 
of several target genes involved in the induction of apoptosis, autophagy and 
cell-cycle arrest. However, we found that oxidative stress and DNA damage 
induced p53 activation did not cause a significant induction of apoptosis or 
autophagy in astrocytes but preferentially induced cell cycle arrest. Specifically 
we found that p53 activation resulted in a significant induction of the cyclin-
dependent kinase inhibitor p21 and a marked reduction in astrocyte 
proliferation as determined by XTT assay and BrdU labelling. These processes 
were found to be p53-dependent as they were abrogated in p53-deficient 
astrocytes. In summary we have determined that the primary effect of p53 
activation in astrocytes in the induction of cell cycle arrest which may limit 
astrogliosis during CNS injury.   
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Chapter 1- Introduction 
1.1 – CNS Neurodegeneration  
Neurodegeneration features prominently in the pathology of many 
diseases including Alzheimer`s Disease, Parkinson`s Disease.  Neuronal loss of 
function is largely responsible for the morbidity and eventual mortality 
associated with these conditions. Neurons and glial cells together constitute an 
integrated system for brain function (Rojo et al. 2008). During the past few 
years, evidence has mounted, suggesting that glial cells play a major role in 
modulating neuronal injury and cell death during neurodegenerative conditions 
(Rojo et al. 2008).  
1.11 – Glia and their role in Neurodegeneration 
There are three major types of glial cells in the CNS: astrocytes, 
oligodendrocytes and microglial cells. Unlike neurons which have little capacity 
to replace themselves when lost, neuroglia can proliferate throughout life 
(Alberts et al. 2004). Both microglia and astrocytes are activated in CNS injury 
and neurodegenerative diseases and can modulate the extent of neuronal 
damage. Microglia constitutes the main innate immune cells of the CNS and 
can modulate the extent of neuronal injury through the release of pro- and 
anti- inflammatory cytokines (Rojo et al. 2008).  
Astrocytes are classically identified as cells expressing the intermediate 
filament glial fibrillary acidic protein (GFAP).  Astrocytes are capable of 
performing several functions that are essential for normal neuronal activity, 
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including glutamate uptake, glutamine release  (Swanson et al. 2004) and 
trophic support by regulating blood flow and maintaining a normal brain 
physiology (Alberts et al. 2004). Astrocytes also play a role in ionic buffering 
(Giaume & Liu 2011), the removal of toxic metabolites and compounds 
(Rappold & Tieu 2010), and they secrete neurotrophins and cytokines that 
influence neuronal functioning (Nakamachi et al. 2011; Hamby & Sofroniew 
2010).  
Astrocyte functions are also utilized when the neurons are under stress. 
For example, astrocytes can promote neuronal survival during ischemia and 
neuronal outgrowth and regeneration in the post-injury period. Astrocytes are 
capable of protecting cells from radioactivity (Koto et al. 2011), exposure to 
astrocyte-conditioned media is protective when neurons are exposed to hypoxic 
environments (Du et al. 2011). The ability of astrocytes to function when 
neurons are stressed can be extremely beneficial for the preservation of 
neuronal functioning and survival.  
 On the other hand, astrocytes are also capable of inducing (Zhang et al. 
2010) apoptosis and other forms of cell death in neurons (Brown & Neher 
2010). In many cases the function of astrocytes can tip the balance between 
neuronal survival and death.   
Astrogliosis, a cellular reaction with specific structural and functional 
characteristics, represents a remarkably homotypic response of astrocytes to a 
variety of neuropathologies and considerable evidence indicates that 
astrogliosis is an underlying component of many of these diseases. Astrogliosis 
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is characterized by an increase of intermediate filaments (GFAP and vimentin) 
with accompanying cellular hypertrophy and an  increase in the number of 
astrocytes (Zhang et al. 2010). The mechanisms underlying reactive astrogliosis 
are not fully understood but the cell cycle control system seems to play an 
important role (McGraw et al. 2001).  
1.12 – Oxidative Stress and Neurodegeneration 
Oxidative stress (OS) plays a central role in neuronal injury and cell 
death in acute and chronic conditions. Bleomycin can result from 
mitochondrial dysfunction, excitotoxicity or neuroinflammation and is 
implicated in the pathology of chronic diseases such as Parkinson’s disease, 
Alzheimer’s disease (Higgins et al. 2010), multiple sclerosis (Haider et al. 2011), 
Amyotrophic lateral sclerosis (Golden & Patel 2009). As well as in acute 
conditions that lead to neuronal death such as stroke and epilepsy (Golden & 
Patel 2009).  Oxidative stress is defined as the imbalance of reactive oxygen 
species (ROS) generation relative to the actions of intrinsic antioxidant 
defences. ROS are chemically reactive molecules containing oxygen. ROS are 
highly reactive due to the presence of unpaired valence shell electrons. They 
form as a natural by-product of normal cellular metabolism however during 
times of environmental stress ROS levels can increase dramatically. The 
cellular response to oxidative stress embraces changes in mitochondria and 
other organelles and ROS is particularly damaging to DNA as the excited ROS 
molecule can react with the DNA components.   
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1.2 – The Structure and Regulation of p53  
A key effector of cell fate decisions in response to oxidative injury and 
DNA damage is p53. P53 acts primarily as a transcription factor, regulating the 
expression of more than 100 target genes to initiate apoptosis, cell cycle arrest, 
DNA repair, cellular senescence and differentiation (Vousden & Lane 2007). It 
has also been reported to translocate to the outer mitochondrial membrane to 
interact with both pro and antiapoptotic proteins and influence the induction 
of both apoptosis and autophagy, physiological relevance of these non-
transcriptional mechanisms are not clear (Chipuk & Green 2003).  
1.21 – p53 Degredation 
Generally, p53 protein accumulation is not considered to be due to an 
enhanced transcriptional response of the cell but the consequence of p53 
protein stabilization mediated by a range of post-translational modifications 
(Bode & Dong 2004). Mouse double minute 2 (Mdm2), the predominant 
negative regulator of p53 normally maintains p53 at low levels within the cell  
by targeting p53 for degradation. However p53 itself activates the transcription 
of mdm2 creating a  negative feedback loop on p53 (Momand et al. 1992); 
(Chehab et al. 2000; Shieh et al. 2000; Hirao et al. 2000) and transcriptional 
and post-translational inhibition of Mdm2 (Appella & Anderson 2001) (Brooks 
& Gu 2003). Ubiquitination represents an essential activity of Mdm2 for 
regulating the amount of p53 protein within a cell at a given time. Mdm2 acts 
specifically as an E3 ligase for p53 by linking E2-conjugated ubiquitin 
molecules to it via an isopeptide bond (Zhang & Xiong 2001). Ubiquitination 
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occurs within the nucleus, p53 is shuttled into the cytoplasm either directly or 
indirectly by Mdm2, and then is recognized by the 26S proteosome for 
degradation (Pickart 2000). p53 can be stabilized by other mechanisms in 
response to stress for example, calpain 1(Kubbutat & Vousden 1997), β-
catenin (Damalas et al. 1999), and JNK (Fuchs et al. 1998) have all been shown 
to stabilize p53 in Mdm2-null cell lines.  
1.22 – p53 Structure and Function  
p53 is composed of 393 amino acids clustered into three functional 
domains: a carboxy-terminal domain, an acidic amino-terminal domain and a 
central sequence-specific DNA-binding domain (Kim et al. 2011; Stommel et al. 
1999).  At least three phosphorylation events take place within the N-terminal 
domain which contains the transactivation domain and occur in response to 
agents that cause cellular stress such as DNA damage. The C-terminus is 
involved in the formation of a tetramer of p53, and this domain also contains 
the locations of three phosphorylation events, each of which can independently 
regulate the specific DNA-binding function of p53, suggesting convergent 
control by different signalling pathways. The multiplicity of these covalent 
modifications and their responsiveness to a wide range of signals suggest that 
p53 activity is tightly and co-ordinately controlled in response to stresses and 
changes in the cellular environment (Chen et al. 1995; Meek 1998; Fields & 
Jang 1990).  
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1.23 – p53 Activation  
The p53 tumour suppressor can be induced through transcriptional, 
post-transcriptional and post-translational control mechanisms.(Sun et al. 
1995; Wang & El-Deiry 2006; Grover et al. 2008; Bode & Dong 2004). The 
sequence specific DNA-binding of p53 and subsequent transactivation of its 
target genes can be modulated by post-translational modifications. These 
include reduction and oxidation reactions (REDOX) which alter cysteine 
residues and DNA binding ability (Hainaut & Milner 1993), and the 
phosphorylation of numerous serine and theronine residues (Bode & Dong 
2004) (Mayr et al. 1995).  
Serine and threonine residues are targets for phosphorylation and are 
mainly located within the N-terminal transactivation domain (TAD) and the C-
terminal domain (CTD) of p53. Various kinases including JNK, HIPk2 and 
many others have been shown to phosphorylate p53 after DNA damage (Bode & 
Dong 2004). Most sites that are phosphorylated in response to a stress signal 
lead to p53 protein stabilization and thereby enhance its function and/or affect 
the binding specificity. 
Acetylation and Methylation can also influence the functions of p53. 
Specifically, p53 can be acetylated at several lysines and lys120-acetylation has 
been shown to cause the preferential accumulation of p53 on the promoter of 
proapoptotic genes including bax and puma (Sykes et al. 2006). Methylation of 
p53 can also occur at two different sites, which are reported to induce opposing 
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effects on p53 function: repression of transcriptional activity or enhancement 
of p53-dependent transcription (Huang et al. 2006). 
 Also, the translational regulation of p53 can be modified in response to 
DNA damage by the ribosomal protein L26 and nucleolin, two interacting 
proteins found in the nucleolin-containing ribonucleocomplex, that bind to the 
5’UTR of p53 mRNA and co-regulate its abundance with opposing functions 
(Takagi et al. 2005). The reduced state of cysteine residues maintains p53 in its 
while-type conformation capable of specific DNA-binding however, oxidation 
disrupts the p53 conformation and thereby inhibits its DNA binding ability 
(Hainaut & Milner 1993).  
The extent of p53 activation is influenced by many factors, including p53 
levels, cofactors, kinases, and the specificity of the RE sequences, all of which 
contribute to the role of p53 in regulating cell fate. Upon the stabilization and 
activation of p53-transcriptional activity a variety of different gene classes can 
be induced. The major functions of p53 are to regulate growth arrest, 
apoptosis, premature senescence and autophagy thus to eliminate damaged or 
stressed cells and to prevent their proliferation.  
1.24 – Posttranslational modifications of p53 and ROS 
 Within the literature, many groups have implicated ROS generation in 
the posttranslational modifications of p53. During cisplatin-induced apoptosis, 
ROS are involved in phosphorylation of p53 that leads to p53-mediated MAPK 
activation(Bragado et al. 2007). ROS is also implicated in the phosphorylation 
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and activation of p53 via oxidative-stress-induced activity of platelet-derived-
growth-factor-β and ATM kinase (Chen et al. 2003).  
1.3 – Growth Arrest  
1.31– Cell Cycle Regulation  
The cell cycle regulatory proteins, which include cyclin-dependent 
kinases (cdks), cdk inhibitors (CKIs), cyclins, and the RB, and E2F families of 
proteins, constitute a network of interacting factors which govern exit from or 
passage through the mammalian cell cycle (Gill et al. 1998). The ability of p53 
to induce cell cycle arrest depends on the three critical target genes: most 
prominently p21 but also 14-3-3σ and GADD45. The activation of p21 triggers 
G1 cell cycle arrest through the inhibition of G1 cyclin-dependant kinases 
(cyclinA/cdk2, cyclinE/cdk2, cyclinD/cdk4 complexes) (Harper et al. 1993). In 
response to DNA damage, cells lacking p21 fail to undergo G1 cell cycle arrest 
but they can still undergo cell death (Brugarolas et al. 1995). Through the 
induction of 14-3-3σ, a cytoplasmic scaffolding protein and GADD45 p53 can 
also induce G2/M arrest in cells that have sustained DNA damage (Wang et al. 
1999). 14-3-3σ has been shown to prevent nuclear import of cyclin B1 and 
CDC2 through sequestration in the cytoplasm (Chan et al. 1999) whereas 
GADD45 destabilizes CDC2/cyclin B complexes (Jin et al. 2002). These two 
processes cooperate to prevent the initiation of mitosis. Although the most 
prominent function of p21 is the mediation of G1 arrest, evidence has been 
presented that it also participates in the G2/M arrest after DNA damage by 
blocking PCNA function at replication forks (Ando et al. 2001). 
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Cyclin-dependant kinases exert positive growth control by inactivating 
negative regulators of the cell cycle, such as the retinoblastoma gene product 
Rb. Maintenance of the RB-E2F complex and consequent inhibition of S phase 
entry then stops cells with a damaged genome from undergoing faulty DNA 
replication, thereby preventing propagation of mutations (Harper et al. 1993). 
Hypophosphorylated Rb functions during the G1 phase to block the activity of 
E2F and related transcription factors that are required for the expression of 
genes involved in S phase (Harper et al. 1993). Proteins that interact with Cdk2 
either as substrates or regulators of Cdk2 activity are likely to have important 
roles in cell cycle transitions.  
p21, has one high-affinity and several low-affinity p53 RE sites. In 
general, binding affinities seem to dictate the choice of regulating cell cycle 
arrest through p21 transcription because of the high-affinity p53 RE sites 
located in the p21-gene promoter region (Yu et al. 1995). 
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Figure 1- Cell Cycle Regulation p53 phosphorylation and acetylation of p53 
by kinases and acetyltransferases allows the transcriptional induction of p21. 
Elevated p21 levels allow an interaction with cyclin-CDKs activity to inhibit the 
cell cycle at G1, the initiation of S, the conclusion of S and the initiation of M 
phases(Harper et al. 1993; Jung et al. 2010).  DNA damage results in the 
induction of GADD45, which destabilizes CDK1/2 and cyclin complexes  (Jin et 
al. 2002). 14-3-3σ has been shown to prevent nuclear import of cyclin B1 and 
CDC2 through sequestration in the cytoplasm (Chan et al. 1999). 
1.32 – The role of p53 in Premature Senescence and Aging  
Cellular senescence can be induced by telomere dysfunction, DNA 
damage, chromatin instability, and oncogene activation. Most normal human 
cells undergo cellular senescence after a fixed number of cell divisions, or 
following challenge with a variety of potentially oncogenic stimuli, in vitro and 
in vivo. Cellular senescence is characterized by an irreversible growth arrest 
11 
 
11 
 
and certain altered functions. Accumulation of senescent cells is thought to 
contribute to age-related pathologies. Senescent cells in culture are identified 
by their inability to undergo DNA synthesis, this property is also shared by 
quiescent cells. Premature senescence is controlled by two major pathways, the 
p16–pRb pathway and the p53–p21 pathway. In fact, p21 was first identified as 
an over-expressed marker in senescent cells  (Noda et al. 1994) and later found 
to be capable of inducing premature senescence in both normal and tumor 
cells in a p53-independent manner (Fang et al. 1999b). P21 contributes to the 
progression of cells into not only cell cycle arrest but also premature 
senescence. 
1.4 – Programmed Cell Death 
1.41 – Apoptosis   
Programmed cell death (PCD) is a physiological process in which 
molecular programs that are intrinsic to the cell are activated to cause its 
destruction. This process is a fundamental property of all multicellular 
organisms and is crucial for proper development (Oppenheim 1991; Vila & 
Przedborski 2003). The importance of PCD is illustrated by its remarkable 
degree of evolutionary conservation.  Opposed to the advantageous role 
apoptosis plays during development, during neurodegeneration, apoptosis is 
extremely detrimental (Schulz et al. 1998; Nitatori et al. 1995; Portera-Cailliau 
et al. 1995). Apoptosis is characterized by specific cellular morphological 
changes including shrinking of the cytoplasm, membrane blebbing, chromatin 
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condensation and DNA fragmentation (Kerr et al. 1972). Necrosis is a distinctly 
different form of cell death which is accompanied by cell-swelling and a 
compromised plasma membrane (Kerr et al. 1972). There are two general 
apoptotic cell death pathways: the extrinsic cell death pathway and the 
intrinsic or mitochondrial cell death pathway (Figure 2) (Strasser & Vaux 
2000). This ultimately leads to cleavage of caspase 3 and apoptosis (Ashkenazi 
& Dixit 1998).  
 The extrinsic pathway as the name implies is induced by a signal from 
the environment surrounding the cell; extracellular ligands bind to death 
receptors and induce apoptosis. The intrinsic pathway begins with activation of 
intracellular pro-apoptotic proteins that leads to changes in mitochondrial 
membrane potential and permeabilization, resulting in the release of 
proapoptotic co-factors into the cytoplasm, such as cytochrome C that in turn 
activate the caspase cascade (Strasser & Vaux 2000; Liu et al. 1997; Liu et al. 
1996). Caspases are cysteine proteases that are present in healthy cells as 
zymogens (Strasser & Vaux 2000) and they are responsible for cleaving 
proteins at specific aspartic acid residues within tetrapeptide recognition 
sequences (Kaufmann & Hengartner 2001).  
Caspases are the main executioners of apoptosis (Salvesen & Dixit 1997) 
and their activation is regulated by a family of pro-apoptotic and antiapoptotic 
members known as the B-Cell lymphoma-like (Bcl-2) protein family (Adams & 
Cory 1998). 
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Figure 2- The Intrinsic Apoptosis Pathway. p53 stabilization and post-
translation modifications can result in the transcriptional activation of Bcl-2 
BH3-only proteins Noxa and Puma. They both directly and indirectly activate 
Bax, which translocates to the mitochondrion to facilitate the release of 
cytochrome C, the activation of the caspase cascade and result in apoptosis. 
(Tsujimoto 2003; Salvesen & Dixit 1997; Li et al. 1997) 
 
1.42 – The Bcl-2 Family  
 Bcl-2 proteins are of critical importance in the induction of PCD; the 
family is comprised of both pro-and anti-apoptotic members (Figure3). They 
interact both at the physical and functional level to regulate mitochondrial 
integrity and apoptotic cell death (Tsujimoto 2003). Different Bcl-2 family 
members are induced depending on the stimulus and cell type. But generally, 
upon activation, proapoptotic family members target the mitochondria and 
cause membrane permeabilization and the release of proapoptotic factors; 
cytochrome-c and apoptosis-inducing-factor(Cregan et al. 2002). When released 
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into the cytoplasm cytochrome-c facilitates activation of the apoptotic 
activating factor-1 (Apaf-1)/Caspase-9 apoptosomal complex that triggers the 
caspase cascade and subsequent cell degradation (Li et al. 1997). Proapoptotic 
factor activation in response to apoptotic stimuli can be regulated by the 
actions of a third class of Bcl-2 family members known as the Bcl-2 homology 
3 (BH-3)-domain-only proteins. BH-3-only proteins, for example Puma (p53-
upregulated mediator of apoptosis) and Noxa, promote apoptosis by binding to 
prosurvival Bcl-2 family members and thus releasing the proapoptotic factors 
from their inhibition and allowing them to induce apoptosis.   
 
 
Figure 3- The Bcl-2 Protein Family. Anti-apoptotic members are multidomain 
proteins that function to antagonize the induction of PCD via direct binding to 
pro-apoptotic multidomain relatives (Bax and Bak) or by an interaction 
between the BH3-only proteins. Pro-apoptotic members are divided into 2 
categories: multidomain members and BH3-only members. Bax and Bak 
contain a C-terminal membrane anchor (TM) permitting their interaction with 
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the outer mitochondrial membrane. The BH3-only subgroup enables apoptosis 
either by interacting with Bax and Bak directly or by sequestering anti-
apoptotic molecules that normally inhibit Bax and Bak.  
1.43 – BH3-Only Proteins and p53   
The intrinsic pathway is typically activated by p53 in response to 
oxidative stress and DNA damage. Gene targeting studies have indicated that 
both p53 and p53-binding sites in the Puma promoter are indispensable for 
induction by DNA damage (Yang & McKeon 2000). Specifically in the CNS, 
transcriptional induction of Puma is essential for oxidative-stress-induced 
neuronal apoptosis and Puma is a key transcriptional target in p53-mediated 
neuronal cell death (Cregan et al. 2004; Steckley et al. 2007) have shown that 
oxidative stress is a potent inducer of pro-apoptotic Bcl-2 members and 
neuronal apoptosis. Puma expression is upregulated in neurons within regions 
of the hippocampus known to exhibit significant levels of apoptosis, suggesting 
that Puma may be an important target in stroke (Reimertz et al. 2003). In 
addition to Puma, it has also been observed that a robust induction of Noxa 
mRNA, another BH-3 only protein, was found in response to certain types of 
oxidative stress. Noxa is also upregulated in cortical and cerebellar granule 
neurons after DNA damage or enforced expression of p53 (Cregan et al. 2004). 
Following oxidative stress and DNA damage, Puma and Noxa are upregulated 
in a p53-dependent fashion, induce apoptosis through the 
intrinsic/mitochondrial pathway in a variety of tissues and cell compartments, 
including but not limited to mouse embryonic fibroblasts (MEFs), neurons, 
thymocytes, the hematopoietic system, spleen and intestinal crypts (Yu & 
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Zhang 2008; Steckley et al. 2007; Reimertz et al. 2003; Nakajima & Tanaka 
2011; Cregan et al. 2004). 
1.5 – Autophagy  
Autophagy is a homeostatic and evolutionarily conserved process in 
which intracellular membrane structures sequester old or damaged proteins, 
macromolecules and organelles for lysosmal degradation. Most autophagic 
proteins (Atgs) are involved in different stages of membrane modifications. 
Microtubule-associated protein light chain 3 (LC3 or Atg8) exists in a cytosolic 
and cleaved, lipid-conjugated form, which is associated with the 
autophagosome membranes LC3 or Atg8 and other autophagy related proteins 
facilitate its formation. Once the formation of the autophagosome is completed 
LC3 remains attached to the membrane, making it an ideal target for 
monitoring autophagosome assembly and localization. The autophagosome 
ultimately fuses with the cell’s lysosmes to form an autolysosme where its 
contents are degraded by lysosomal proteases and its monomer components 
are recycled by the cell  (Hwang et al. 2010; Galluzzi et al. 2010; Budanov & 
Karin 2008; Klionsky & Emr 2000).  
1.51 – Autophagy and p53  
A basal level of autophagy occurs in most cells to maintain proper 
organelle and protein functioning, however a higher turnover rate can be 
induced by cellular stress. This helps to ensure the survival and proper 
functioning of a cell (Szumiel 2011). Recent literature has shown that p53 is 
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capable of altering the rate of autophagy under certain conditions. When p53 is 
present in the cytoplasm it represses autophagy in a transcription-independent 
fashion, while nuclear p53 stimulates autophagy through the transcriptional 
activation of specific genes: Sestrin2 and damage-regulated-autophagy-
modulator (DRAM). This has been shown in the literature first by Crighton and 
colleagues. DRAM, a p53-target gene encoding a lysosmal protein was shown to 
induce autophagy. Also, p53 includes autophagy in a DRAM-dependent 
manner: DRAM alone was sufficient to induce autophagy in p53-null cell lines 
(Crighton et al. 2006b). And in another study, the depletion of Sestrin2 or 
DRAM by RNA interference prevented autophagy induction in a p53-sufficient 
human cancer cell line responding to autophagy inducers (Maiuri et al. 2009). 
Recently, the involvement of autophagy in the pathophysiology of 
neurodegenerative diseases has attracted considerable interest because 
autophagy deregulation has been linked to some of these disorders. 
1.6 – Cerebral Injury and p53  
Neuronal apoptosis is mediated by the mitochondrial pathway, which has 
been shown to be induced by p53, in the majority of neurodegenerative 
diseases. With respect to ischemic cell death enhanced p53-immunoreactivity 
has been detected in both neurons and reactive astrocytes in cortical regions 7 
days following ischemic injury when the undamaged control had no evidence of 
p53 expression (Chung et al. 2002). While it has also been noted that p53 is 
upregulated in astrocytes following spinal cord injury (Kotipatruni et al. 2011) 
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and X-radiation (Wang et al. 2011)  the precise role of p53 within astrocytes in 
response to cell stress has not been defined.  In the case of spinal cord injury, 
immunohistochemical analysis appears to indicate that p53 is upregulated 
within the nucleus and sparsely in the cytoplasm. A full spinal cord section 
was homogenized and p53 homologous proteins, cell-cycle regulatory proteins, 
Bcl-2 family proteins, DNA-repair proteins and apoptosis-regulatory proteins 
all showed increases in their levels of mRNA when compared to a sham control. 
While the experiment was not specific to one cell type, some of these genes 
could be indicating changes in regulation in astrocytes (Kotipatruni et al. 
2011). p53 was found to be elevated following hydrogen peroxide treatment in 
glial cell lines, with an associated  decrease in mdm2 levels (Bonini et al. 2004). 
Recently, p53 was found in cortical astrocytes following X-irradiation (Wang et 
al. 2011).  
The precise mechanism of astrocyte signalling following oxidative stress 
has not been determined and examining the involvement of p53-response 
genes and possible pathways of p53 involvement can be explored to better 
understand how astrocytes can cope with assaults that kill neurons. Also, 
perhaps better understand the supportive relationship that exists between 
astrocytes and cortical neurons following oxidative stress and DNA damage 
(Belanger & Magistretti 2009).  
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1.7 - Rationale 
Neurodegeneration features prominently in the pathology of many 
diseases.  Oxidative stress (OS) plays a central role in neuronal injury and cell 
death in acute and chronic conditions. Bleomycin can result from 
mitochondrial dysfunction, excitotoxicity or neuroinflammation and is 
implicated in the pathology of chronic diseases such as Parkinson’s disease, 
Alzheimer’s disease (Higgins et al. 2010), multiple sclerosis (Haider et al. 2011), 
Amyotrophic lateral sclerosis (Golden & Patel 2009). As well as in acute 
conditions that lead to neuronal death such as stroke and epilepsy (Golden & 
Patel 2009).  The cellular response to oxidative stress embraces changes in 
mitochondria and other organelles and ROS are particularly damaging to DNA 
as the excited ROS molecule can react with the DNA components.  p53 is 
frequently activated to serve as a signalling molecule in response to both DNA 
damage and oxidative stress in a variety of tissues, including the CNS to 
induce a variety of end points. As mentioned, astrocytes can modulate 
neuronal fate in both stressed and unstressed conditions and the literature has 
noted that p53 is upregulated in both neurons and astrocytes following DNA 
damage and oxidative stress but its function and mechanism of action within 
astrocytes in largely unclassified. The goal of this work is to examine the role of 
p53 within astrocytes following oxidative stress and DNA damage.  To describe 
this role, I will determine the pattern of its upregulation following oxidative 
stress and DNA damage, if transcriptional-target genes are upregulated 
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following p53 accumulation and if apoptosis, autophagy or cell-cycle arrest is 
preferentially activated.   
1.8 – Hypothesis and Objectives  
We hypothesize that p53 activation will trigger apoptotsis, autophagy, 
cell cycle arrest and/or pre-mature senescence in primary cortical astrocytes.   
Objective: To examine the potential role of p53 in the astrocyte injury response.  
a) Determine if p53 is upregulated in primary cortical astrocytes in 
response to Bleomycin and Camptothecin  
b) Determine if p53 is transcriptionally active and whether distinct classes 
of p53-response genes are induced in astrocytes (Cell Cycle Arrest and 
senescence; P21, Autophagy; DRAM, Sestrin-2, Apoptosis; Puma and 
Noxa) 
c) Determine whether p53 activation in astrocytes triggers apoptosis, cell 
cycle arrest, senescence or an elevated rate of autophagy  
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Chapter 2 – Materials and Methods 
2.1 – Primary Astrocyte Cultures  
 Astrocytes were extracted from the brains of 1-day-post-natal mouse 
pups (p1) from pregnant CD1 females purchased from Charles River 
Laboratories. The P1 pups were dissected to remove the cerebral cortices, 
cleaned of their meninges and pooled then kept on ice for 1 hour in a solution 
of HBSS (Invitrogen - #14170). The solution of cleaned cortices was centrifuged 
for 5 minutes at 300 g and the supernatant was removed. The cell pellets were 
resuspended in complete astrocyte media which was composed of Dulbecco's 
Modified Eagle Medium (DMEM Invitrogen-#11960), 10% Fetal Bovine Serum 
(FBS) (Invitrogen-#11960), 1mM glutaMAX TM (Invitrogen-#35050-061) and 
50μg/ml gentamycin (Invitrogen-#15710). The suspended cortices were 
triturated in a 10mL serological pipette into a homogenous solution. The 
suspended cortex solution was divided into equal portions, to be plate one pup 
per flask and plated onto a poly-D-lysine (VWR-#CACB354210) coated  353110 
– BD Falcon 75cm ² Cell Culture Flask and stored in a humidified 37˚C  
incubator at 5% CO₂  (humidified incubator) overnight.  The media was then 
exchanged for fresh media to remove any debris from the triturated tissue. The 
cells were then left to incubate for 7 days. Flasks were shaken overnight at 300 
rpm on orbital shaker in a humidified incubator. The flasks were washed with 
1x PBS 3 times and trypsinzied with 0.25% Trypsin-EDTA (Invitrogen-#25200) 
and then media containing serum was applied to stop the trypsinization. The 
concentration of cells was determined by manual counting using a 
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haemocytometer under a light microscope. The solution of cells was then 
adjusted to a concentration of 500 000 cells per ml for plating  on 60 mm 
(VWR- # CA25382-330) poly-D-lysine coated dishes, or 100 000 cells per ml for 
6 well, 50 000 per ml for 12 well, 25 000 per ml for 24 well or 10 000 per ml for 
96 well plates.  
2.2 – Genotyping (p53 WT, het KO) 
 P53 knockout mice were obtained from The Jackson Laboratory, 
specifically C3Ou.129S2 (B6)-Trp53tmiTyj/J(#002547). Tail samples from each 
pup were dissolved in DNA lysis buffer, which contains 100mM Tris buffer, 
5mM EDTA, 0.2% SDS, 200mM NaCl, and 0.2 mg/ml Protienase K (Invitrogen-
#25530-015). Each tail sample was shaken vigorously and placed in a 55˚C dry 
bath overnight to ensure complete digestion.  
 The DNA was isolated by phenol-chloroform extraction. An equal volume 
of phenol-chloroform was added to each tail sample from a solution of 
phenol:chloroform:iso-amyl alcohol (25:24:1). Each tube was thoroughly 
shaken for 10 minutes, and then centrifuged at 12, 000 g for 10 minutes at 
room temperature. The resulting upper aqueous phase was carefully 
transferred to a new set of tubes, avoiding contamination with the interphase, 
and 500 μl of cold 95% isopropanol was added to each tube. The tubes were 
shaken vigorously until a visible DNA precipitate was observed. Samples were 
centrifuged at 12,000 g at 4 ˚C  for 10 minutes.  
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 After aspirating the supernatant, 1ml of 70% ethanol was added to each 
tube and mixed by inversion. Samples were centrifuged  at 12, 000g for 5 
minutes at 4 ˚C. Once again the supernatant was removed leaving the DNA 
pellet damp. The excess ethanol was evaporated from each open tube following 
10 minutes in a 55 ˚C heat block. The DNA pellets were then resuspended in 
50 μl of 1x TE buffer (pH 8.0). To ensure complete dissolution, all of the tubes 
were incubated at 37˚C in a dry bath for 1 hour. DNA concentration and 
quality (260nm/280nm) were then determined by UV spectrophotometry. Each 
sample was the used as a template in PCR for genotyping.  The DNA samples 
were then prepared for PCR including a previously determined positive control 
sample and a negative control. The reagents, cycling conditions, primer 
sequences and expected product can be found in Table 1. Following the PCR, 5 
μl of 6x loading dye was added to each sample and then loaded, with a 1 kb+ 
ladder (Fermentas-#SM1331), onto a 1.5% ethidium bromide-stained agarose 
gel bathed in 1 x TAE buffer. After a 30 minute run at 120V, the PCR products 
were visualized under UV light on a gel dock system. For the p53 experiments, 
each pup was dissected and triturated separately and plated on separate BD 
Falcon 75cm ² Cell Culture Flask.   
2.3 – Drug Treatments 
Drug treatments were administered to the cortical astrocytes 3 days after 
plating. Each drug was diluted from a stock solution with the appropriate 
volume of media to arrive at the desired final concentration. All relevant 
information for each drug used in this work is detailed in Table 2.  
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2.4 – Hoechst-33342 Stain 
After 24, 48, 72 and 96 hours of exposure to drug treatment, the 12-well 
dishes were prepared for fixing and staining. The media from each dish was 
removed by aspiration and replaced with 500μL of Lana’s Fixative, (4% 
paraformaldehyde (Sigma-#P6148), 160mM dibasic and monobasic sodium 
phosphate, and 0.2% picric acid (Sigma-#80456)). The plates were left to 
incubate at room temperature for 30 minutes at which point the fixative was 
gently aspirated off and the cells were washed twice with  1x PBS pH 7.4. 
Hoescht-33342 dye (Sigma-#861405) was diluted to 1μg/mL in 1xPBS pH7.4 
and 500μL aliquots of this solution were added to each well. The cells were 
stained for 30 minutes and covered with aluminum foil to prevent light 
exposure. The staining solution was aspirated off from each well and replaced 
with 500μL of 1xPBS pH7.4.  
Imaging was performed with a 40x objective lens and ultra-violet (UV) 
light using an Olympus IX70® fluorescence microscope (Olympus America 
Microscope) and digital camera connected to a computer running Northern 
Eclipse 7.0 software. Images were captured from at least four representative 
locations per well. For each treatment, at least 300 nuclei were counted in each 
experiment. The morphology of the nuclei were evaluated as either healthy, 
apoptotic (shrunken and/or fragmented), or necrotic (swollen).  The number of 
apoptotic nuclei were divided by the total number of healthy and apoptotic 
nuclei counted per well to get the percentage of apoptosis for the treatment.  
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2.5 – LIVE/DEAD Assay 
 A live/dead assay kit was performed according to the manufacturer’s 
protocol (Invitrogen -#L34958).  Live cells were distinguished by the presence of 
ubiquitous intracellular esterase activity, determined by the enzymatic 
conversion of the nonfluorescent cell-permeant calcein AM to the intensely 
fluorescent calcein (494/517nm). The polyanionic dye calcein is retained within 
live cells, producing an intense uniform green fluorescence in live cells. 
Ethidium homodimer-1 (EthD-1) accumulates in cells with damaged 
membranes and undergoes a 40 fold enhancement of fluorescence upon 
binding to nucleic acids thereby producing a bright red fluorescence in dead 
cells (495nm-635nm). At least 500 cells were counted per treatment, and the 
percentage of dead cells was determined for all treatments by scoring the 
percentage of dead cells over the total cells per image.    
2.6 – Quantitative Real Time-Polymerase Chain Reaction  
The cells were harvested in Trizol® (Invitrogen-# 15596) and RNA 
extracted from cells according to the manufacturer’s protocol. The 
concentration of each sample was calculated in duplicate by using a Nanodrop 
3300 UV spectrophotometer (Thermo FisherScientific -#ND3300). RNA samples 
were diluted in DNase, RNase-free H₂0 at a concentration of 5ng/μL.  
One step qRT-PCR was performed using a QuantiFast SYBR green qRT-
PCR kit (Qaigen-#204243) and carried out on a PTC-200 thermocycler and 
Chromo4 florescence detector, from BioRad. The reagents, cycling conditions, 
and primer sequences for the qRT-PCR are summarized in Table 3. 
26 
 
26 
 
qRT-PCR results were recorded and analyzed using the Opticon Monitor 3.0 
program for the Chromo4 fluorescence detector. The delta cycle threshold (ΔCt) 
method was used to calculate the fold change in mRNA levels relative to 
untreated control samples for each transcript and normalized to an internal 
transcript, ribosomal S12 in treated cells. The cycle threshold was set 
manually within the exponential phase of the reaction for each independent 
experiment. The equation used to calculate fold change in the gene of interest 
(G.O.I) mRNA levels was:  
Fold Change= 2^(G.O.I. Ct CTRL- G.O.I. Ct Treated)  
  2^(S12Ct CTRL- S12 Ct Treated)   
All PCR reactions exhibited similar efficiencies (≥90%) . RT-PCR products 
were confirmed via sequencing to determine primer specificity. Additionally, a 
melting curve was run to validate the presence of a single precise product.  
2.7 – Western Blot  
Cells were gently washed in 1x PBS and then harvested in RIPA lysis 
buffer (10mM Tris-HCL, 1mM EDTA, 150mM sodium chloride, 0.1% SDS, 1% 
NP40, 5μg/ml aprotinin, 5μg/ml leupeptin, 1mM PMSF, 1mM DTT) and 
incubated on ice for 30 minutes. Samples were then centrifuged at 12000g for 
12 minutes at 4 degrees Celsius. Resulting supernatant was collected for 
protein determination using the Pierce ©BCA protein determination assay, as 
per manufacturer’s instructions (#22325 Thermo Fisher Scientific ©) 30-50μg 
of protein of each sample were subjected to SDS-PAGE and transferred to a 
nitrocellulose membrane by semi-dry electroblotting. The membranes were 
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blocked with 10% (w/v) powdered milk in wash buffer (150mM NaCl, 10mM 
Tris, 0.05% Tween-20) for 1 hour at room temperature. The membranes were 
the rocked overnight at 4 oC with a primary antibody diluted in wash buffer 
containing 5% (w/v) powdered milk. The primary antibodies used in this study 
were anti-Actin (I-19) (Santa Cruz SC-#1616) diluted to 1:10 000, anti-p53 (IC-
12) (Cell Signalling-#2524) diluted to 1:1000, and anti-LC3 diluted to 1:1000 
(Novus Biologicals NB100-2331).  
Membranes were rinsed with wash buffer three times for 10 minutes on 
an orbital shaker at room temperature. Membranes were incubated with the 
secondary antibody and rocked for 1 hour at room temperature.  The 
secondary antibody used was a horseradish peroxidise (HRP) – conjugated goat 
anti-rabbit or mouse IgG prepared in a dilution of 1:10 000 in wash buffer 
containing 5% (w/v) powdered milk. The membranes were then rinsed in wash 
buffer 3 times for 10 minutes. The immunoblotted proteins were detected by 
chemiluminescence with SuperSignal West Pico Chemiluminescent Substrate 
(Pierce-#34080) and exposed to Kodak BioMax Maximum sensitivity film (#829 
4985). 
2.8 – XTT Assay  
After 24, 48, 72 and 96hrs astrocyte proliferation was assessed using an 
XTT Assay according to the manufacturer’s protocol (Roche- #11 465 015 001). 
Three replicates were averaged per time point and treatment to make a single 
n-value. To eliminate background absorption, the absorbance values were 
normalized to an unmetabolized XTT control well for every treatment and time 
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point.  This was done to determine an assessment of proliferation after each 
treatment. A percentage result was determined by taking the average treated 
well absorption (Ta), averaging 3 replicates, and then of the absorption of the 
untreated control (Ca) value. 
   
           
 
  
   
           
 
 
           
  
  
      
 
2.9 – Adenoviral Infection  
A LC3 –fused-GFP expressing adenovirus was created in our lab by 
Jennifer Guadagno, PhD candidate following the protocol found in (Cregan et 
al. 2000). Multiplicity of infection (MOI) is the ratio of infectious adenovirus 
particles to cells.  The astrocytes were infected with an MOI of 10, a titer at 
which >90% of astrocytes were GFP positive.  
2.10 – Visual Assessment of Autophagy  
 Images of the LC3-GFP were captured using an Olympus Florescence 
microscope at 3hrs, 5hrs, 24hrs and 48hrs following treatment.  Astrocytes 
were counted as positive for autophagy when the number of LC3-GFP puncta 
was greater than 10 within that cell.  The measurement of cells undergoing 
autophagy was represented as a percentage of the total number of cells per 
image. At least 300 cells were counted per treatment.   
2.11 – β- Galactosidase Stain 
 β-galactosidase staining was used to assess if the astrocytes were 
becoming senescent following treatment with  camptothecin or bleomycin. The 
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reagents used can be found in Table 4. Cells were grown in 24-well dishes. To 
Fix, the cells were washed twice with 1x PBS. The fixative (Table 4) was 
prepared immediately prior to use, and then applied to the cells for 3 min 
(500μl per well). The fixative was aspirated and then the cells were washed 3 
times again with 1x PBS. Complete X-gal stain (Table 4) was applied for 16hrs 
in a humidified 37˚C 5% C0₂ incubator. The stain was then removed and the 
cells washed twice with PBS 1x. Cells were imaged on an Olympus Microscope. 
The images were not able to be captured in color so the cells positive for β-
galactosidase expression were counted live and represented as an average of 
the total number of cells.  
2.12 –Bromodeoxyuridine Test  
 Cell proliferation was assessed using a BrdU Assay according to the 
manufacturer’s protocol (Millipore-#2750). Astrocytes were plated at 50% 
confluence on a 96 well plate. 32 hours following treatment with a media 
control, CPT or bleomycin the astrocytes were pulsed for 16 hours with BrdU 
reagent. With CHEMICON®'s BrdU Cell Proliferation Assay Kit, mouse 
monoclonal antibody is used to detect the BrdU in a sample at 48 hours 
following treatment. After addition of goat anti-mouse IgG-peroxidase 
conjugated secondary antibody, substrate and stop solution, the amount of 
BrdU that was incorporated into the DNA of replicating cells is determined. 
Optical density is proportional to the BrdU concentration within the sample. 
The presence of BrdU causes the production of a coloured compound that can 
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be detected by a plate reader. The absorbance of each treated cell normalized 
by a background reading and was plotted for comparison.  
2.13-Immunostain for GFAP 
Primary astrocyte cultures were grown on 4-well plates and were fixed for 
30 min in Lana’s Fix. Cells were washed twice with PBS and then incubated for 
20 min at 22°C in 0.1% Titron X-100 in PBS and 3% bovine serum albumin to 
permeabilize cells and block non-specific sites. Cells were then incubated in 
PBS-TB containing anti-GFAP antibody (Chemicon International AB5804 
1:250) for 45 min at room temperature, washed twice with PBS, and incubated 
for an additional 45 min in PBS-TB containing Alexa Fluor 488 (Molecular 
Probes) anti-rabbit IgG (1:500). Cells were then incubated with Hoechst Stain 
for 20 min. Cells were then washed twice with PBS and stored at 4°C until 
imaged using an Olympus Florescence microscope.  
2.14 – Data Analysis 
Data was reported as mean and standard deviation. The value N 
represents independent astrocyte cultures of defined genotype. Differences 
between groups were determined by either a unpaired Student’s T-Test or a 
one-way ANOVA followed by Dunnets`s post hoc tests. Data was considered 
statistically significant when p <0.05. All statistical analyses were conducted 
using GraphPad Prism software version 5.0 (GraphPad software, San Diego, 
CA).  
 
31 
 
31 
 
Chapter 3- Results 
3.1 – Glial Fibrillary Acidic Protein Confirms that Cultured Cells are 
Astrocytes 
 GFAP is a well accepted marker to distinguish astrocytes from other 
neuronal cells types both in vivo and in vitro (Chung et al. 2002; Pekny & 
Nilsson 2005).  Primary astrocytes were fixed and immunostained for GFAP 
and (Figure 4).  Hoescht-33342 was used as a nuclear marker. Virtually all of 
the cells expressed GFAP, indicating that the cells are astrocytes.  
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Figure 4 – GFAP Positive Primary Astrocytes - Primary Astrocytes 
immunostained for GFAP (green) and Hoescht-33342 nuclear stain (blue), scale 
bar = 50μM.  
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3.2 - p53 is induced by DNA damage and oxidative stress  
 Free radicals produced during oxidative stress can lead to lipid 
peroxidation and DNA damage and in many types of cells this results in 
activation of p53. Therefore, we first sought to determine whether oxidative 
stress and/or DNA damage can induce p53 activation in astrocytes. 
Bleomycin chelates metal ions such as iron, which react with oxygen to 
produce superoxide and hydroxide free radicals that are capable of damaging 
organelles, causing lipid peroxidation and damaging genomic DNA. Bleomycin 
has previously been shown to induce p53 activation in many types of cells 
(Davis et al. 2000). 
Camptothecin is a quinoline alkaloid which irreversibly binds to the 
DNA-topoisomerase I complex, inhibiting the reassociation of DNA after 
cleavage by topoisomerase I and traps the enzyme in a covalent linkage with 
DNA. The enzyme complex is ubiquinated and destroyed, thus depleting 
cellular topoisomerase I and causing significant DNA damage (DD)(Fan et al. 
1998). 
Therefore Bleomycin and Camptothecin were used in this study to 
investigate the role of p53 in astrocytes in response to oxidative stress and DNA 
damage respectively.  
To determine if p53 is induced in astrocytes by bleomycin and 
camptothecin, protein was collected 24 hours post-treatment and p53 protein 
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levels were assessed by western blot (Figure 5). Robust expression of p53 was 
found following both Bleomycin and Camptothecin treatment and this was 
sustained for at least 72 hours following treatment. 
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Figure 5 - DNA damage and oxidative stress induce p53 in primary 
astrocytes.  
Astrocytes were treated with Camptothecin (10μM) or Bleomycin (100μM) and 
protein was collected at 24, 48, and 72 hours following treatment and p53 and 
Actin levels were assessed by western blot. Representative images of 5 
independent experiments are shown (n=5). 
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3.3 - P53 is transcriptionally active in Astrocytes following DNA 
damage and Oxidative Stress  
 P53 was found to be induced and sustained within primary astrocytes 
following treatment with both an oxidative stressor and a DNA-damaging agent. 
There are multiple functions of p53; most important of which is its ability to 
induce the transcription of cell pathways involved in determining cell fate. 
Such pathways can result in apoptosis, autophagy, cell-cycle arrest, and 
premature senescence. Quantitative RT-PCR (qRT-PCR) was used to examine 
several important p53-target genes, each strongly associated with a particular 
cell-fate pathway.  Primary astrocytes were exposed to Bleomycin or 
Camptothecin and mRNA was collected at several time points following 
treatment to examine the expression of p53 target genes associated with 
apoptosis, autophagy or cell cycle arrest.  
3.31- Apoptosis Related Transcripts 
Noxa and PUMA were chosen as representative p53-target genes capable 
of inducing apoptosis because numerous studies have illustrated that both can 
be instrumental in mediating the induction of apoptosis in many different cell 
types following p53 induction (Adams & Cory 1998; Adams & Cory 2007; Yu & 
Zhang 2008; Wu & Deng 2002). NOXA was induced at all time points following 
bleomycin treatment (p< 0.05) 24 and 48hrs following CPT (p<0.05, n=4) 
(Figure 6). PUMA was significant 72hrs following CPT and Bleomycin (p<0.05, 
n=4).  This result indicates that p53 is transcriptionally active in astrocytes 
following Camptothecin and OS, and induces the expression of pro-apoptotic 
target genes.  
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To determine if this induction is dependent on p53 these experiments 
were repeated in p53 wild-type and knockout primary astrocytes and indicated 
that this induction is indeed p53 dependent.  
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Figure 6 Following Oxidative Stress and DNA damage, Noxa and PUMA are 
transcriptionally activated.   
Primary astrocytes were treated with CPT (10μM) or Bleomycin (100μM) 
and mRNA was collected at 24, 48, 72hrs. The mRNA levels of (A) Noxa and (B) 
Puma were determined by qRT PCR and was reported as a fold increase relative 
to untreated control cells and normalized to  S12 mRNA (*p<0.05, n=4). (C) 
Noxa induction is diminished in the p53 null astrocytes, 48hrs after treatment 
(*p<0.05, n=3). Data was analyzed by using an unpaired t-test. 
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3.32 - Autophagy Related Transcripts  
 Autophagy levels can be greatly induced to ensure the survival and 
proper functioning of a stressed cell (Szumiel 2011).  p53 is one such 
modulator of increased autophagy within a cell. One way p53 influences 
autophagy induction is by activating the transcription of DRAM and Sestrin2. 
To examine the possibility of elevated autophagy levels within astrocytes 
following oxidative stress, Sestrin-2 and DRAM were chosen as p53-inducible 
autophagy mediators.  Sestrin2 and DRAM have been shown to be p53-
inducible modulators of stress-induced autophagy upregulation. To determine 
if p53 was inducing autophagy related gene targets, the mRNA transcript levels 
of Sestrin2 and DRAM were examined using qRT PCR. 
Sestrin2 mRNA levels were found to be elevated several fold above that of 
an untreated control (Figure 7A).  DRAM induction however, was not induced 
(Figure 7B). This indicates that autophagy may be upregulated in response to 
elevated p53 levels within astrocytes following Bleomycin and CPT treatment 
due to the mRNA upregulation of Sestrin2 though not DRAM.   
To determine if the upregulation of Sestrin2 is p53-dependent, the 
experiment was repeated in p53 wild-type and knockout primary astrocytes 
(Figure 7C).  The p53-knockout cells had significantly diminished transcription 
of Sestrin2 following both treatments, (*p<0.05, n=3). 
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Figure 7 - Following Oxidative Stress and DNA damage, Sestrin2 not 
DRAM is transcriptionally activated.  Primary astrocytes were treated with 
CPT (10μM) or Bleomycin (100μM) and mRNA was collected at 24, 48, 72hrs. 
The mRNA levels of (A) Sestrin2 and (B) DRAM was determined by qRT-PCR 
and is reported as a fold increase relative to untreated control cells and 
normalized to S12 mRNA. (C) Sestrin2 induction is diminished in the p53 null 
astrocytes, 48hrs after treatment (*p<0.05, n=3). Data was analyzed using an 
unpaired T-test.  
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3.33 - Cell-Cycle Arrest 
 It has been known for decades that p53 can induce cell-cycle arrest 
following DNA damage by transcriptional activation of target genes(Shen et al. 
1983).  One of the most common and influential target genes especially in 
response to DNA damage is p21(Ando et al. 2001; Brugarolas et al. 1995; 
Harper et al. 1993; Fang et al. 1999a). To determine if p53 could be inducing 
cell-cycle arrest or premature senescence through transcriptional activation, 
the mRNA transcript levels of p21 were examined using qRT PCR.   
The cell-cycle and premature senescence regulator p21 was found to be 
induced by both Bleo and CPT treatments 48 and 72hrs following treatment 
(Figure 8A). This data suggests that p53 could be inducing cell-cycle arrest 
and/or premature senescence following Bleomycin and Camptothecin through 
the p53-target gene p21.  
To determine if the upregulation of p21 is p53-dependent, the experiment 
was repeated in p53 wild-type and knockout primary astrocytes (Figure 8B).  
The p53-knockout cells had significantly diminished transcription of p21 
following both treatments, (*p<0.05, **P<0.01, n=3). 
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Figure 8 - Oxidative Stress and DNA Damage induce p53-dependent p21 
expression at the mRNA level  
(A)Primary astrocytes were treated with CPT (10μM) or Bleomycin (100μM) and 
mRNA was collected at 24, 48, 72hrs. p21 mRNA levels were determined by 
qRTPCR and are reported as a fold increase relative to untreated control cells 
and normalized to mRNA levels of S12 mRNA.  
(B) Primary p53 wild-type and knockout astrocytes were treated with CPT 
(10μM) or Bleomycin (100μM) and mRNA was collected at  48 hours and p21 
mRNA levels were determined by qRT-PCR and are reported as a fold increase 
relative to untreated control cells and normalized to S12 mRNA levels . p21 
induction is diminished in the p53 null astrocytes, 48hrs after treatment 
(*p<0.05,**P<0.01, n=3). Data was analyzed using an unpaired T-test 
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3.4 - DNA damage and Oxidative Stress Induce p21 Protein 
Expression  
 Protein levels are not exclusively determined by transcriptional control 
mechanisms. To confirm that p53-target genes also show an elevated protein 
level following Bleomycin and Camptothecin treatments, protein was isolated 
and evaluated by western blot. The observed p21 mRNA levels following 
Camptothecin and Bleomycin found by qRTPCR were also translated to result 
in an elevation at the protein level (Figure 9). We were unable to detect Puma or 
Noxa protein by western blot but it is unclear whether this is due to poor 
quality antibodies or very low levels of these proteins. 
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Figure 9  - P21 protein levels were elevated following CPT and Bleomycin 
treatment In the top panels, primary astrocytes were exposed to DNA damage 
(CPT 10μM) and Bleomycin (Bleomycin 100μM) and after 24, 48, 72 and 96hrs 
p21 (21kDa) protein levels were assessed (n=4). Actin was used as a loading 
control.  
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3.5 - Oxidative Stress and DNA damage do not induce apoptosis in 
astrocytes  
 In some cell types, p53 activation can induce apoptosis. It was found 
that two different p53 target genes capable of inducing apoptosis were 
upregulated following CPT and Bleo treatment: Noxa and Puma (Wu & Deng 
2002; Okamura et al. 2001; Yu & Zhang 2008; Cregan et al. 2004).  
Apoptosis is an endpoint that can be assessed by using a number of 
measures. One characteristic of apoptosis is nuclear blebbing and chromosome 
condensation; these morphological changes can be assessed using Hoechst 
33342 stain, which fluorescently labels the nuclei. Therefore, we used Hoechst 
33342 stain to quantify the number of apoptotic astrocytes following treatment 
with camptothecin or bleomycin. As shown in figure 10, neither camptothecin 
nor bleomycin treatment resulted in a significant increase in the fraction of 
apoptotic cells over a 96 hour time frame. However, staurosporine treatment 
resulted in a marked induction of apoptotic cells suggesting that astrocytes are 
capable of undergoing apoptosis.  
 The astrocytes were shown to be capable of inducing apoptosis through 
the use of staurosporine. To ensure that staurosporine was capable of doing 
this independently of p53 and to reaffirm that p53 does not induce apoptosis in 
this paradigm: p53 null astrocytes were treated with either staurosporine or a 
media control. The p53 null cells induced apoptosis in the same manner as the 
p53 sufficient cells in all previous experiments (Figure10C). 
48 
 
48 
 
 
49 
 
49 
 
Figure 10 DNA damage and oxidative stress do not induce apoptosis in 
Astrocytes. (A) Primary astrocytes plated at 50% confluence and treated, cells 
were visualized with Hoechst 33342 the percentage of apoptotic nuclei treated 
with Staurosporine is significant (*p<0.0001) at all time points n=5. Data was 
analyzed using a 1-way ANOVA and a Dunnets Post test.  
 (B) Representative images of the quantified results in panel A. 200x 
magnification. Scale bar= 50μM. 
(C) Primary astrocytes derived from p53 knockout mice were treated with 
either Staurosporine (1μM) or a media control. The cells were stained with 
Hoechst 33342 48 hours following treatment. The untreated cells maintain 
normal nuclear morphology where as the staurosporine treated cells induced 
apoptosis and exhibit characteristic nuclear condensation Scale bar = 50 μm, 
n=3.  
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3.6 - Oxidative Stress and DNA damage do not induce cell death in 
astrocytes 
To determine if the astrocytes were dying by another means other than 
apoptosis or if death could not be accurately represented by nuclear 
morphology alone, a second stain was used LIVE/DEAD ®. As shown in figure 
11 Live/Dead staining  revealed that the astrocytes  were not dying when  
treated with  CPT or  Bleomycin, whereas treatment with staurosporine 
resulted in a significant increase in the fraction of dead cells  (*p<0.01, 
**p<0.001). Taken together these results suggest that p53 activation by CPT or 
Bleomycin does not induce apoptotic or non-apoptotic death in astrocytes.  
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Figure 11 DNA damage and oxidative stress do not induce cell death in 
astrocytes. (A) Primary astrocytes plated at 50% confluence and treated, cells 
were visualized with LIVE/DEAD® viability stain,  the percentage of dead cells 
treated with a very high concentration of staurosporine was significant 
(*p<0.01, **p<0.001) at all time points (n=5). 
 (B) Representative images of the quantified results in panel A. 200x 
magnification, scale bar= 50μM.  
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3. 7 - Oxidative Stress or DNA Damage do not induce apoptosis in 
growth inhibited (confluent) astrocytes  
 
To ensure that growth inhibited astrocytes did not induce apoptosis 
upon treatment with an oxidative stress or DNA damaging agent, another 
experiment was conducted. Primary astrocytes were allowed to grow to 
confluence prior to treatment; cells were visualized with Hoechst nuclear stain. 
The percentage of cells with condensed nuclei following treatment with 1μM 
Staurosporine was the only treatment in which cells were inducing apoptosis to 
a significant effect. This indicates that cells that are not actively dividing do not 
induce apoptosis following Bleomycin and Camptothecin induced p53-
induction (*p<0.001) (Figure12).  
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Figure 12 DNA damage and oxidative stress do not induce apoptosis 
in confluent astrocytes. - Primary astrocytes plated and grown to 100% 
confluence then treated and visualized with Hoechst 33342. The percentage of 
apoptotic nuclei treated with Staurosporine is significant (*p<0.001) at all time 
points n=5 The data was evaluated by a 1-way ANOVA and a Dunnet’s post-
test for each time point individually. 
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3.8 - p53 Activation by DNA Damage does not induce autophagy in 
Astrocytes 
 Previous studies have indicated that P53 can promote autophagy 
through a mechanism involving the transcriptional upregulation of Sestrin-2 
and/or DRAM (refs) (Levine & Kroemer 2008).  We have determined that 
Sestrin-2 mRNA levels are induced by Bleomycin and Camptothecin in a p53-
dependent manner therefore we examined whether p53 activation resulted in 
elevated rates of autophagy in astrocytes.   
Bafilomycin A1 (BA1) is an inhibitor of vacuolar ATPase and as a result 
promotes the accumulation of autophagic vacuoles by preventing their 
disassembly; specifically it inhibits lysosomal catabolic activity and thereby 
prevents autophagosome degradation within lysosomes (Shacka et al. 2006). 
This can be used to both assist in the visualization of autophagy upregulation 
by accumulating vacuoles within the cell as well as determine if autophagy is 
necessary for survival. Serum starvation is a common inducer of autophagy 
and was used as a positive control treatment. (Kabeya et al. 2000; Fass et al. 
2007) 
Most autophagic proteins (Atgs) are involved in different stages of 
membrane modifications. Atg8 is the only Atg protein that is covalently 
associated with all autophagic membrane states. LC3 exists in a cytosolic and 
a lipid-conjugated form, which is associated with the autophagosome 
membranes (Fass et al. 2007).  Mutational analyses suggest that LC3-II is 
formed by the removal of the C-terminal, this can be qualitatively measured by 
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western blot, in which a conversion of a fraction of LC3-I into LC3-II can be 
visualized(Kabeya et al. 2000). 
To determine if autophagy was being induced beyond the normal 
homeostatic rate, two complementing experiments were conducted.  
The first experiment (Figure 13A) consisted of astrocytes infected with an 
adenovirus expressing LC3-GFP , and following CPT treatment, the cells were 
imaged and the number of cells with greater than 10 puncta (autophagic 
vesicles) per cell were counted and deemed autophagy positive (Crighton et al. 
2006b). Only serum starvation and serum starvation with Ba1 induced a 
statistically significant increase in the percentage of cells autophagy positive 
(p<0.001, n=3).  
Representative images of punctate and diffuse LC3-GFP florescence can 
be found in Figure 13B. Untreated cells show a diffuse distribution within the 
the cytoplasm of the astrocytes. Upon serum starvation the diffuse appearance 
changes into a punctate appearance throughout the cytoplasm consistent with 
its association with autophagic vacuoles.  
In the second experiment (Figure 13C) an increase in the rate of 
autophagy is implied when the level of LC3-II increases relative to the level of 
LC3-I. However the accumulation of LC3-II surpasses the LC3-I pool only 
following serum starvation treatment (with and without the inhibitor BA1) 
while there is no visible increase in the LC3-II pool relative to the LC3-I pool 
following CPT treatments with or without the inhibitor BA1.  
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Figure 13 - Autophagy is not upregulated following Oxidative Stress and 
DNA Damaged induced p53 expression. (A and B) Representative images, of 
untreated (24hr) and Serum Starved (5hr) left panel 200 x magnifications and 
the right panel is cropped and enlarged.  (C)Primary astrocytes were infected 
with an adenovirus expressing LC3-GFP, and then treated with a vehicle 
control, 10 μM CPT, or Serum Starvation: each with or without Bafiolmycin1. 
Astrocytes were assessed for punctate LC3 distribution patterns and 
quantified. The data was analyzed by a 1-way ANOVA and a Dunnet’s post-test 
for each time point. Serum starvation and serum starvation with Ba1 induced 
a statistically significant increase in the percentage of autophagy positive cells 
(p<0.001, n=3).  (D) Primary astrocytes were treated with a vehicle control, 10 
μM CPT, and Serum Starvation (5 hours): each with or without Bafiolmycin1 
and assessed by western blot for LC3 expression. LC3 I represents reserve pool 
of LC3, LC3 II is localized to autophagosomes and runs at a higher 
electrophoretic mobility due to its decreased size. Elevated LC3 II levels relative 
to LC3 I indicate upregulation of autophagy. As seen in Serum starvation lanes 
with and without Ba1. Scale bar = 50 μM 
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3.9 - Astrocytes have Diminished Proliferative Abilities Following 
Oxidative Stress and DNA Damage 
Since the astrocytes did not appear to be undergoing cell death following 
p53 activation, we next wanted to determine whether p53 was inducing cell 
cycle arrest and inhibiting astrocyte proliferation. We addressed this using an 
XTT proliferation assay in which the relative number of cells is determined by 
measuring the cleavage of the tetrazolium salt XTT into its coloured formazan 
salt. This conversion only occurs in viable cells. Cells grown in a 96-well tissue 
culture plate are incubated with the XTT labelling mixture for approximately 20 
hours. After this incubation period, the formazan dye formed is quantified 
using a scanning multi-well spectrophotometer (Figure 14). The absorbance 
directly correlates to the cell number. We found that CPT (10μM) resulted in a 
significant decrease in the number of cells compared to the untreated control 
at 72 and 96 hours following treatment. Bleomycin was significant at 48, 72 
and 96 hours.  
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Figure 14 – DNA damage and oxidative stress decrease astrocyte 
proliferation. Proliferation of primary astrocytes treated with CPT (10μM) and 
Bleo (100 μM) cells were assessed with an XTT Proliferation Assay. CPT and 
Bleomycin resulted in a significant decrease in the number of cells compared to 
the untreated control, ***p<0.0001, **p<0.01 n= 4. The data was analyzed by a 
1-way ANOVA and a Dunnet’s post-test for each time point 
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3.10- Oxidative Stress and DNA damage induced altered 
Proliferation is p53-dependent  
 To confirm that the altered proliferation was p53-dependent the XTT 
Proliferation Assay was repeated in p53 wild-type and knockout primary 
astrocytes. Primary astrocytes deficient or wild type for p53 were plated at 50% 
confluence and treated, cells were visualized with XTT Proliferation Kit II 24, 
48, 72 and 96 hours after treatment. The number of wild-type astrocytes 
following Bleo treatment was significantly different from that of the p53-
knockout cells (Figure 15A, n=3, * p<0.01) at 48 hours following treatment, and 
significant to a p<0.001 (**) at 72 and 96 hours following treatment. The 
number of wild-type astrocytes following Camptothecin treatment was 
significantly different from that of the p53-knockout cells (Figure 15B) at 48, 
72 and 96 hours following treatment. This indicates that the Bleomycin and 
Camptothecin induced p53 expression causes the decreased proliferative 
abilities of primary astrocytes. 
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Figure 15 Decreased Astrocyte proliferation is p53-dependent. Primary 
p53-knockout and wild-type astrocytes were treated with CPT (10μM) and 
Bleomycin (100μM) and the cell were assessed with an XTT Assay.  
(A)Bleomycin was significant at 48 to 96hrs following treatment, (* p<0.05, ** 
p<0.001), n=3. 
(B)Camptothecin was significant at 48, 72 and 96 hours following treatment 
(**p<0.001, ***P<0.0001), n=3.  The data was analyzed by a Student’s T-test for 
each time point.  
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3.11 - p53 Activation by Oxidative Stress and DNA Damage inhibits 
Cell Replication 
To confirm that the decreased XTT activity was attributable to cell cycle 
inhibition we next performed pulse labeling experiments with the thymidine 
analog bromodeoxyuridine (BrdU). BrdU is incorporated into newly synthesized 
DNA strands of actively proliferating cells and is detected immunochemically 
allowing the assessment of the population of cells which are actively 
synthesizing DNA. 
Any cells that were proliferating at the time of the pulse were labelled 
and quantified as a measure of absorbance at 450nm. As shown in figure 16 
p53 deficient astrocytes  had a significantly greater concentration of BrdU 
positive label following either CPT or Bleomycin treatment than wild type 
astrocytes, (***p<0.001, n=3). This indicates that the cells deficient for p53 
were proliferating following treatment, whereas p53-wildtype astrocytes were 
unable to proliferate (Figure 16).  
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Figure 16 - Oxidative Stress and DNA damage decrease the number of 
astrocytes undergoing cell division in a p53-dependent manner. Primary 
p53 knock-out and wild-type astrocytes were treated with CPT or Bleomycin 
and incubated with a pulse of BrdU reagent. Any cells that were proliferating at 
the time of the 16 hour pulse were labelled and quantified as a measure of 
absorbance at 450nm. The knockout cells had a significantly greater 
concentration of BrdU positive label following CPT treatment, ***p<0.001, n=3. 
As well as following Bleo treatment, *p<0.05, n=3. The data was analyzed by a 
Student’s T-test for each time point.  
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3.12 – Oxidative Stress causes premature senescence in a minority 
of primary astrocytes.  
 Senescence β-galactosidase Staining Kit is designed to detect β-
galactosidase activity at pH 6, a known characteristic of senescent cells not 
found in pre-senescent, quiescent or immortal cells. Limited capacity to 
replicate is a defining characteristic of most normal cells and culminates in 
senescence, an arrested state in which the cell remains viable. Senescent cells 
are not stimulated to divide by serum or passage in culture, and senescence 
invokes a specific cell cycle profile that differs from most damage-induced 
arrest processes or contact inhibition. An enlarged cell size, expression of pH-
dependent β-galactosidase activity, and an altered pattern of gene expression 
further characterize senescent cells. 
 Primary astrocytes were treated with Bleomycin or Camptothecin and 
stained with x-galactosidase at 24, 48 and 72 hours. This showed a significant 
induction of senescence through β-galactosidase expression. However this was 
not in the majority of the astrocytes, peaking at 10-15% of the total number of 
cells. The astrocytes treated with CPT did not induce senescence in a 
significant number of cells when compared to that of the untreated control 
(Figure 17).  
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Figure17 – Oxidative Stress Induced Primary Astrocytes to Become 
Senescent.  Primary Astrocytes treated bleomycin (100μM) showed significant 
β-galactosidase expression 72hrs following treatment when compared to that of 
an untreated control (*p<0.01, n=3). The data was analyzed by a 1-way ANOVA 
and a Dunnet’s post-test for each time point 
 
 
 
 
 
 
 
 
 
67 
 
67 
 
Chapter 4 - Discussion 
4.1 - P53 is Induced by DNA Damage and Oxidative Stress  
It is known that many factors, including intracellular levels of p53, 
posttranslational modifications, presence of cofactors, cell type and intensity of 
stress signals are important for determining the p53 response to different cell 
stressors. For example, it has been shown that ROS accumulation can induce 
p53 expression to influence p53-mediated cell fate decisions including 
apoptosis or senescence (Chen et al. 1996). We found that robust expression of 
p53 was induced following treatment with CPT and Bleo (Figure5) and protein 
levels persisted from 24 hours to 72hr hours. This is consistent with a great 
number of cell types that show increased p53 stability following genotoxic and 
oxidative stress (Wu & Deng 2002; Takagi et al. 2005; Sun et al. 1995), and 
also within astrocytes most recently by Wang and colleagues (Wang et al. 
2011).  The sustained expression is of interest as a negative feedback 
relationship exists between p53 and mdm2. p53 itself induces the expression of 
mdm2 which serves to prevent unnecessary accumulation of the potent cell-
signalling regulator. After binding to p53, Mdm2 inhibits p53 transcriptional 
activity, favours its nuclear export and stimulates its degradation(Chen et al. 
1995). Since p53 is allowed to accumulate within astrocytes, this is most likely 
an active process and p53 is executing some function that remains to be 
determined.   
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4.2 – Apoptosis is Not Induced by Oxidative-Stress-and-DNA-
Damage-Induced p53 in Primary Astrocytes 
4.21 – Assessment of Apoptosis and Cell Death Following Oxidative Stress and 
DNA Damage 
In many cell types, an accumulation of p53 can induce apoptosis 
through the intrinsic apoptotic pathway. Several experiments were conducted 
to determine if this was occurring in astrocytes. Primary astrocytes; actively 
dividing and growth inhibited did not induce apoptosis following oxidative 
stress and DNA damage. However, we found that staurosporine could induce 
apoptosis even in p53 deficient astrocytes suggesting that apoptotic pathways 
were functional and that this was independent of p53 (Figure9). To determine if 
the astrocytes were dying by another means other than apoptosis, a second 
stain was used, LIVE/DEAD ® but this also revealed that the astrocytes were 
not dying (Figure 11A and B).  
4.22 – p53 Transcriptional-Target Genes  
To date, transcriptional factor p53, and Bcl-2 family proteins are known 
to play fundamental roles in death processes in response to oxidative 
stress(Banasiak et al. 2000). The BH-3 only proteins Puma and Noxa are well 
known executers of p53-mediated apoptosis. Puma mRNA was found to be 
elevated 5 or 6 fold greater than that of the untreated control level. Noxa mRNA 
levels were also found to be elevated to at least 20 fold greater than the 
untreated astrocyte mRNA levels (Figure 6A and B). This was significantly 
diminished when the experiment was repeated in p53 knock-out astrocytes, 
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indicating that this induction of transcription was indeed dependent on p53 
(Figure 6C).  
As astrocytes do not induce apoptosis following treatment despite the 
presence of p53 and its apparent upregulation of both Puma and Noxa stable 
mRNA, there is likely a downstream block preventing this signalling message 
from inducing the intrinsic apoptotic pathway. Pro-apoptotic BH-3 only 
proteins, particularly Puma, is an extremely potent inducer of apoptosis and as 
a result its transcription is very tightly regulated (Yu & Zhang 2008; Steckley et 
al. 2007).  
The localization and control of Bcl-2 proteins on mitochondria is 
essential for the intrinsic pathway of apoptosis (Lindsay et al. 2011), the BH3-
only proteins of Bcl-2 family are essential initiators of apoptosis. The 
interaction of BH-3 only proteins with other Bcl-2 family members is critical for 
understanding the core machinery that controls commitment to apoptosis by 
permeabilizing the mitochondrial outer membrane and releasing pro-apoptotic 
factors. BH-3 only proteins promote apoptosis by both directly activating Bax 
and Bak and by suppressing the anti-apoptotic proteins at the mitochondria 
and endoplasmic reticulum. Anti-apoptotic Bcl-2 family member protein levels 
could potentially compensate for the elevated Puma and Noxa levels. Bcl-2 can 
directly inhibit Bax and Bak which are normally activated by BH-3 only 
proteins to induce apoptosis, thus inhibiting this activation. Bcl-XL inhibits 
mitochondrial permeabilization via multiple mechanisms including recruiting 
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and binding to BH3-only proteins, many BH3 proteins bind to anti-apoptotic 
Bcl-2 family members (Kim et al. 2004). Elevated levels of antiapoptotic Bcl-2 
family members could prevent the BH-3 only proteins from inducing apoptosis 
in astrocytes.  
Also, while PUMA is a potent inducer of apoptosis, its transcription may 
be upregulated but the protein may be unstable within astrocytes and 
degraded prior to its ability to effectively induce apoptosis. It has been noted 
that posttranscriptional control of p53 target genes can occur (Zhang & Chen 
2008) limiting which target genes are capable of downstream effects. This also 
could explain why Puma expression levels could not be detected by western 
blot. The translation of NOXA could also be inhibited in astrocytes under these 
conditions. But in some systems, even when Noxa protein levels are elevated, it 
has other functions and is often not sufficient to induce apoptosis alone 
(Ghiotto et al. 2010).  
4.3 – P53 does not induce an Elevated Rate of Autophagy in 
Primary Astrocytes 
Many cell types do not induce apoptosis following the induction of p53, 
for example Crighton and colleagues found that p53 through the 
transcriptional induction of DRAM upregulated autophagy (Crighton et al. 
2006b). Sestrin2 has been shown to be induced by autophagy-inducing stimuli 
and to play a role in p53-dependent autophagy upregulation following pro-
autophagic stimuli (Maiuri et al. 2009).    
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4.31 –Visual Assessment of Autophagy in Primary Astrocytes  
A visual assessment of autophagy was conducted using an LC3-GFP 
expressing adenovirus, and only astrocytes that were serum starved showed a 
dramatic induction of autophagy (Figure 13). This begins to indicate that the 
p53 upregulation in astrocytes in response to oxidative stress and DNA damage 
was not inducing autophagy.  
4.32 – Qualitative Assessment of Autophagosome-Bound LC3 Accumulation 
Western blot technique was used to qualitatively assess the conversion of 
diffuse to autophagosome-bound LC3. And while both forms are present in 
astrocytes indicating a basal rate of autophagy is occurring, again the p53 
induction following treatment does not appear to be inducing autophagy in 
astrocytes (Figure 13).  
4.33 – p53 Transcriptional-Target Genes  
Lastly, Sestrin2 mRNA levels were found to be induced 72hrs following 
CPT treatment and 48hrs following Bleomycin treatment (Figure 7A). The 
observed upregulation of Sestrin2 was p53-dependent as the induction was lost 
when the experiment was repeated in p53 knock-out cells (Figure 7C). Despite 
the upregulation of Sestrin2, stress-induced autophagy was not observed 
(Figure 13).  
While Sestrin2 was induced by the presence of p53, it has other 
functions in addition to inducing autophagy in stressful conditions. Including 
antioxidant functions and this function has been shown to be induced by 
modest levels of p53 in some cell types. Sestrins can regulate ROS through 
their direct effect on antioxidant peroxiredoxin proteins and through the AMP-
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activated protein kinase-target of rapamycin signalling pathway. Sestrin2 could 
be mildly upregulated in astrocytes but the end result is that of an antioxidant 
function rather than the induction of autophagy (Lee JH et al, 2011).  
The induction of autophagy in astrocytes could be inhibited by Bcl-2 
family members. Recent studies have suggested possible molecular 
mechanisms for crosstalk between autophagy and apoptosis. Bcl-2 and Bcl-xL, 
the well-characterized apoptosis guards, appear to be important factors in 
autophagy by inhibiting Beclin 1-mediated autophagy by binding to Beclin 1. In 
addition, Beclin 1, Bcl-2 and Bcl-xL can cooperate with Atg5 or Ca 2+ to 
regulate both autophagy and apoptosis. Thus, an elevated level of Bcl-2 anti-
apoptotic proteins that could be responsible for the inhibition of apoptosis 
could also be inhibiting stress-induced autophagy (Sasi et al. 2009; Kang et al. 
2011; Zhou et al. 2011). 
There are other signalling networks between p53 and autophagy. 
Through the activation of both p53 and JNK pathways, p53 regulates JNK 
activation which in turn modulates autophagy through two distinct 
mechanisms: on the one hand it promotes Bcl-2 phosphorylation resulting in 
the dissociation of the Beclin1-Bcl-2 complex and on the other hand it leads to 
the upregulation of DRAM, a p53 target gene. To determine if high levels of 
anti-apoptotic proteins of the Bcl-2 family are mechanistically responsible for 
the inhibition of both autophagy and apoptosis in astrocytes the relative levels 
of Bcl-2 and Bcl-XL as well as their association with Bax could be examined 
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using immunohistochemistry. This would allow for a subcellular localization 
analysis of endogenous levels of these proteins as well as provide a measure of 
the relative levels of these proteins within primary astrocytes in both stressed 
and unstressed conditions.  
4.4 – Oxidative Stress and DNA Damage induced p53 Activity 
Induces Cell-Cycle Arrest in Primary Astrocytes 
4.41 – Assessment of a Decreased Proliferative Ability by XTT Assay 
Next we wanted to determine if the astrocytes were altering their 
proliferative abilities in response to the DNA damaging agents or oxidative 
stressors. An XTT proliferation assay was used and it was found that DNA 
damage and oxidative stress resulted in a discrepancy between the quantity of 
astrocytes in the treated wells compared to the untreated (Figure 15). Since it 
has already been shown that astrocytes do not induce cell death following 
these treatments, and the discrepancy between numbers of cells increases over 
time, it can be inferred that untreated control cells continue to proliferate 
within the wells while those cells treated with CPT or Bleomycin are stalled by 
their treatments. 
To ensure the altered proliferation was p53-dependent the XTT 
Proliferation Assay was repeated in p53 wild-type and knockout primary 
astrocytes. Primary astrocytes deficient or wild type for p53 were plated at 50% 
confluence and treated. The number of wild-type astrocytes following 
Bleomycin or CPT treatment was significantly different from that of the p53-
knockout cells (Figure 15A and B). This indicates that the change in 
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proliferative ability following both oxidative and DNA damage is dependent on 
the presence of p53.  
4.42 – Assessment of Decreased Proliferative Ability by Bromodeoxyuridine 
  Bromodeoxyuridine was used as a measure of actively proliferating cells 
by labelling those that are synthesizing DNA. Primary p53-sufficient astrocytes 
treated with Bleomycin or CPT had a significantly lower optical density than 
that of the treated knockout cells (Figure16). This indicates that the 
proliferative ability of astrocytes is significantly diminished following oxidative 
stress and DNA damage and reinforces that this is dependent on the function 
of p53.   
4.43– p53 Transcriptional-Target Genes 
The cell-cycle and senescence regulator p21 was found to be induced by 
both Bleomycin and CPT treatments (Figure 8A). The elevated p21 mRNA was 
translated to an increase in p21 protein as well confirmed by western blot 
(Figure 9). This data suggests that p53 could be inducing cell-cycle arrest 
and/or premature senescence following Bleomycin and Camptothecin through 
the p53-target gene p21. To determine if the upregulation of p21 is p53-
dependent, the experiment was repeated in p53 wild-type and knockout 
primary astrocytes (Figure 8B). To confirm this, introducing exogenous p21 in 
p53-null astrocytes would confirm that it is p21 alone that is responsible for 
executing the actions of p53 in response to DNA damage and oxidative stress.   
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This data suggests that p53 could be inducing cell-cycle arrest and/or 
premature senescence following oxidative stress and DNA damage through the 
p53-target gene p21.  This induction of p21 following Camptothecin 
complements what was found by Wang and colleagues and within the spinal 
cord(Wang et al. 2011; Kotipatruni et al. 2011).  
4.44 – Assessment of Senescence by β-Galactosidase expression  
P21 contributes to the progression of cells into not only cell cycle arrest 
but also senescence and has been shown to be capable of inducing 
premature (Fang et al. 1999c). β-galactosidase activity is a known 
characteristic of senescent cells not found in pre-senescent, quiescent or 
immortal cells. Limited capacity to replicate is a defining characteristic of most 
normal cells and culminates in senescence: an arrested state in which the cell 
remains viable. Senescent cells are not stimulated to divide by serum or 
passage in culture, and senescence invokes a specific cell cycle profile that 
differs from most damage-induced arrest processes or contact inhibition.  
 Primary astrocytes treated with Bleomycin but not Camptothecin showed 
a significant induction of senescence through β-galactosidase expression 
(Figure17). However this was not in the majority of the astrocytes, peaking at 
10-15% of the total number of cells.  
The culmination of this work indicates that oxidative stress and DNA damage induces 
the expression of p53 in primary astrocytes. A graphic representation of the 
experimental process can be found in the appendix (Figure 18).  
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This causes decreased proliferative abilities and this is likely due to the 
increased expression of known cell-cycle inhibitor p21. Future work could 
confirm this by attempting to rescue the growth-stalled astrocytes by 
exogenously introducing p21 in p53-knock-out astrocytes and assessing their 
proliferative abilities.  
 The proliferation of astrocytes following damage often results in reactive 
astrogliosis: a combination of hypertrophy and hyperplasia that leaves a scar 
devoid of neuronal function and drastically reduces the ability for axonal 
regrowth through this scarred tissue. They have the potential for neuronal 
toxicity; secreting nitric oxide radicals and other ROS (Ikeda & Murase 2004).  
Astrogliosis is also believed to be responsible for some beneficial actions. 
Ablation of scar-forming reactive astrocytes shows that these cells are essential 
for the spatial and temporal regulation of inflammation of CNS injury (Bush et 
al. 1999). Astrocytes also produce both pro- and anti-inflammatory cytokines 
and secrete molecular guidance cues that influence the migration of many cell 
types(John et al. 2003). They also stimulate blood-brain-barrier repair and 
counteract edema (Bush et al. 1999).  
In this work, astrocytes are growth arrested by oxidative stress and DNA 
damage, two treatments which mimic the stress typically found in both chronic 
and neurodegenerative diseases. p53 activation has the potential to limit 
astrogliosis in vivo by inhibiting the excessive hyperplasia associated with the 
stress response. This, in theory, could benefit the repair effort by allowing for 
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greater axonal regrowth and minimize the size of the glial scar. However, 
because this work is in vitro and conducted with a monoculture of astrocytes 
the role of p53 may be less influential when astrocytes are bombarded by 
additional extracellular factors from neurons, microglia and oligodendrocytes in 
response to the oxidative and genotoxic stresses. p53 activation may also 
inhibit any benefit from the astrocytes growth and expansion and overall 
hinder the repair of the damaged area.  In an effort to answer these questions, 
role of p53 could be determined in vivo by using pifithrin-α, a commonly used 
p53 inhibitor.  It is known that inhibiting p53 in neurons prevents apoptotic 
cell death which may allow for the preservation of neural function at the site of 
injury. However, if p53 action within astrocytes is also inhibited; this work 
indicates that inhibiting p53 could exacerbate the injury and cause excessive 
astrogliosis and overwhelm the surviving neurons with astrocytes. In response 
to oxidative stress and DNA damage, astrocytes are growth inhibited, likely 
through the activation of p53 and p21, however the role of p53 in vivo and 
whether this activation will help or hinder neuronal repair is uncertain.   
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Chapter 5- Summary and Conclusions 
 In this work we have shown that p53 induction occurs in primary 
astrocytes following both oxidative stress and DNA damage and that this 
induction induces cell-cycle arrest rather than apoptosis: as in neurons 
(Cregan et al. 2004) or autophagy as in other cell types (Crighton et al. 2006a). 
We have implicated that p53 induction results in the transcription and 
translation of p21, a known cell-cycle inhibitor often mediated by p53.  Also 
that while p53 appears to be activating the transcription of apoptosis-and-
autophagy-inducing genes, the end points of these cell signalling networks do 
not occur. This could imply a downstream signalling block that exists in 
astrocytes but not other cell types. The induction of cell-cycle arrest does not 
result in the majority of cells becoming permanently senescent.  
In conclusion a closer investigation of the mechanistic role of p21 in 
orchestrating the induction of p53-dependent cell-cycle arrest following 
oxidative stress and DNA damage could help to alleviate the stress on the 
central nervous system caused by reactive astrogliosis: a pathogenesis heavily 
determined by the extensive proliferation of astrocytes following stress. As well 
in a larger sense, a better understanding of the response of the astrocyte to 
stress can help to illustrate the dynamic relationship that exists between 
neurons and astrocytes as part of the pathology of neurodegenerative diseases.   
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Chapter 6 – Appendix 
Table 1: p53 Genotyping  
Fermentas PCR Reagents for Genotyping of p53 KO Mice 
P53 Wildtype P53 Knockout 
Reagent Volume 
10x Buffer (+KCl-MgCl₂)                                 
2.50 
25mM MgCl₂                                                     
1.75 
2.5 mMdNTPs                                                  
2.00 
5μM p53 WT1                                                  
1.25 
5μM p53 WT2                                                  
1.25 
1U/μL Taq DNA polymerase                          
1.25 
H20 (DNase-free)                                          
13.00 
 23.00 
DNA template (0.5μg/μL)                               
2.00 
Total                                                                 
25.00       
Reagent Volume 
10x Buffer (+KCl-MgCl₂)                                 
2.50 
25mM MgCl₂                                                     
1.75 
2.5 mMdNTPs                                                  
2.00 
5μM p53 Neo                                                   
1.25 
5μM p53 x7                                                      
1.25 
1U/μL Taq DNA polymerase                          
1.25 
H20 (DNase-free)                                          
13.00 
 23.00 
DNA template (0.5μg/μL)                               
2.00 
Total                                                               
25.00       
PCR Cycling Conditions for Genotyping of p53 KO Mice  
1. 94oC for 5 min 
2. 94oC for 1 min 
3. 55oC for 1 min 
4. 72oC for 5 min 
2-4 repeated 32 cycles 
5. 72oC for 10 min 
6. 10oC indefinitely 
Primers for Genotyping of p53 KO Mice 
P53 Wildtype P53 Knockout 
Sense- p53 WT1:  
5’-GTATCTGGAAGACAGGCAGAC-3’ 
Antisense- p53 WT2:  
5’-TGTACTTGTAGTGGATGGTGG-3’ 
Sense-p53 Neo: 
5’-TTCCTCGTGCTTTACGTATC-3’ 
Antisense-p53 x7: 
5’-TATACTCAGAGCCGGCCT-3’ 
Expected PCR Products for Genotyping of p53 KO Mice 
Wildtype Band: 500bp 
Knockout Band 600bp 
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Table 2: Drug Information  
 
Name 
 
Effects 
 
Compan
y 
Catalog
ue 
 
Number 
Stock 
Concentrat
ion 
(mM) 
 
Solve
nt 
Final 
Concentrat
ion (μM) 
Camptothecin DNA Damage 
DNA-
topoisomerase I 
complex 
Inhibitor 
Sigma C9911 10 DMSO 10 
 
Staurosporine Induces 
apoptosis 
inhibitor of 
protein kinase 
C.  
Sigma S6942 1 DMSO 1 
Bleomycin 
Sulfate 
Oxidative Stress 
Binds to oxygen 
and a metal ion 
to 
cleave DNA  
Sigma B8416 7 H₂0 100 
Bafilomycin 
A1 
Inhibitor of 
vacuolar 
H+ ATPase 
Inhibitor of 
autophagolysoso
me 
formation 
Sigma B1793 100 DMSO 10nM 
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Table 3: Quantitative Real-Time Polymerase Chain Reaction  
Qiagen © Reagents for Quantative RTPCR of p53 Response Genes and S12 
Reagent 
2x QuantiFast SYBR Green RT-PCR 
Master Mix 
5μM Forward Primer 
5μM Reverse Primer 
DNase RNase-free Water 
QuantiFast RT Mix 
 
10ng/μL 
Total 
Volume (μL) 
12.50 
3.00 
3.00 
2.25 
0.25 
21.00 
4.00 
25.00 
Cycling Conditions  
1. 50˚C for 30min 
2. 95˚C for 15min 
3. 94˚C for 25sec 
4. 58˚C for 30sec 
5. 72˚C for 40sec 
6. Plate Read  
7. 72˚C for 5min 
8. Repeat #4-7, 36 Cycles  
9. Melting curve 65˚C to 95˚C, read every 0.2˚C, 
hold 1 sec 
10. END 
Primers for qRT-PCR  
Gene 5’-Sense-3’ 3’-Antisense-5’ 
p21 ACCACGTGGCCTTGTCGCTG TCTTGCAGAAGACCAATCTGCGCT 
Sestrin2 TCCGAGTGCCATTCCGAGAT TCCGGGTGTAGACCCATCAC 
PUMA AGCACTTAGAGTCGCCCGT GAGGAGTCCCATGAAGAGATTG 
NOXA GCAGAGCTACCACCTGAGTTC CTTTTGCGACTTCCCAGGCA 
DRAM ATTTCTTGGCGCAGCTACGAT CACGGCTAACTCCTGGAAGT 
S12 GGAAGGCATAGCTGCTGG CCTCGATGACATCCTTGG 
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Table 4: β-Galactosidase Reagents 
Fixative 
Reagent Concentration Catalogue Number 
2.0% Formaldehyde 
0.2% Glutaraldeyde 
In 1x PBS Filtered (0.2μM) 
 Sigma-# F8775 
Sigma-# G6257 
Staining Solution  
Reagent Concentration Catalogue Number 
Potassium hexacyanoferrate(II) 
trihydrate  
Potassium hexacyanoferrate(III) 
Sodium Chloride 
Magnesium Chloride 
Sodium Citrate Dihydrate 
Sodium phosphate dibasic 
5-Bromo-4-chloro-3-indolyl β-D-
galactopyranoside (x-gal) 
5 mM 
5 mM 
150mM 
2mM 
40mM 
to pH 6.0 
1mg/ml 
Sigma-#455989 
Sigma-#455946 
Sigma-#S7653 
Sigma-#M8266 
Sigma-# W302600  
Sigma-# S3264 
Sigma-#857211 
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Figure 18: Experimental Outline. First it will be determined if p53 is 
upregulated in astrocytes following treatment with Camptothecin and 
Bleomycin. Next qRT-PCR will be used to determine what transcriptional target 
genes will be induced by the upregulation of p53.  The third row illustrates the 
experiments that are used to determine if apoptosis, autophagy or cell-cycle 
arrest are the endpoint induced by the presence of p53 in astrocytes.  
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